Concurrently, the European Society for Medical Oncology (ESMO) issued an expert consensus encompassing four critical dimensions: include biological characteristics, pathological diagnosis, clinical treatment and clinical trial design of HER2-low breast cancer. This evidence concerns the gene ERBB2 and breast cancer.